The global coagulation analyzers & reagents market size was worth USD 3.3 billion in 2015 and is likely to grow at a CAGR of over 10.2% over the forecast period. The growth of this market is supported by increasing number of lifestyle disorders and chronic blood related disorders.
The increase in the volume of testing can be attributed to the augmented awareness among people towards lifestyle and blood disorders which is expected to further improve the diagnostic rate and preventive care management. The study covers developing countries which are undergoing paradigm shift and are highly investing government funds for the procurement and installation of these medical devices in the public healthcare facilities.
Specifically, for the developing nations of the Asia Pacific and Middle East region factors such as increased geriatric population, rapid growth in foreign investments and rising prevalence of lifestyle disorders are expected to be support market growth. Another major driving force identified is the increased incidence of haemophilia as per a report published by the WHO, resulting in the industry growth and rising installation base and expansion of these medical devices in the healthcare facilities.
Analyzers are one of the most critical and important equipment used for diagnosis, currently owing to multiple factors and thus are expected to have a lucrative CAGR in the forecasted period. The major factors driving the growth of this segment are increasing incidences of the lifestyle disorders such as diabetes, cardiovascular disorders and obesity combined with developing healthcare infrastructure and spending on healthcare.
The factor expected to propel the growth of the diagnostics market, are providing timely and quality care to the patients which in turn is expected to hike the demand for hemostasis analyzers. The class of hemostasis analyzers recording the majority of the shares in 2015 is the clinical laboratory analyzers which are predominantly used in the hospitals for the hematological analysis of the patients on a daily basis.
Shares up to 65.0% were held by the Consumables segments which were further sub segmented to stains and reagents. Due to the pre requisite of having reagents for each and every test, their demand also increases with increase in diagnostic volume, hence a high repository of orders are placed by the hospitals. The sales of these consumables are expected to be boosted by the higher volumes of testing and development of new and innovative assays.
Over the period of forecast, optical technology is estimated to hold majority of the shares due to the increasing combination of photo optical method with immunologics and chromogenics. This combination has led to the development of multipurpose, high performance optical hemostasis analyzers.
This segment is further divided into chromogenic/immunological/photo optical and others. The other segment includes technologies that are patented by Beckman Coulter Inc., Instrumentation Laboratory, Siemens Healthcare and others.
Test Type Insights
In the context of test types, maximum shares were recorded to be held by the prothrombin segment followed by the APTT test segment in 2015. High popularity among the physicians for the aforementioned tests is responsible for the large shares.
The APTT test is majorly used in the detection of coagulation inhibitors, inherited and acquired abnormalities of the intrinsic coagulation pathway, liver diseases, monitoring of heparin therapy and Disseminated Intravascular Coagulation (DIC). The various principles on which this test is based are electrochemical and photo optical.
The major drivers for the end-use segment of the coagulation analyzer market are rapid expansion in primary healthcare centers and hospitals, favorable government regulations in the healthcare facilities combined with availability of advanced equipment with capacity to perform high accuracy multiple tests.
The major end users of this market are research institutes, hospitals, diagnostic centers and others. In 2015, diagnostic centers dominated the market due to the high rates of outsourcing of the diagnostic tests to these centers, but in the forecasted period hospitals are expected to grow due higher number of installations of analyzers and consumables on the basis of hospital needs.
North America held majority of the revenue shares in 2015 for the global market, which is around 35.0%. The major drivers for this region are increasing prevalence of disorders belonging to the cardio metabolic class like Pulmonary Embolism (PE), and Deep Vein Thrombosis (DVT) and presence of well-established healthcare services.
Regions such as Middle East and Africa are expected to show higher growth rates due to the growing number of hospitals, health centers and clinics combined with highly skilled professionals to provide useful, appropriate and safe healthcare facilities. In 2012 Ministry of Health and Ministry of Public Works announced an investment worth USD 4.4 billion aimed at expansion and replacement of nine operating hospitals in the span of next ten years, following which a National Health Plan was created for the span of 2010-2014 focusing on major expansions in the healthcare sector.
Major players in the market are namely Siemens Healthcare, Instrumentation Laboratory, and Roche Diagnostics, Alere, Inc., Thermo Fischer Scientific, and Nihon Kohden. Due to the easy global accessibility in this market, the major players are already present in across various countries and are competing to secure the higher market share.
Distributions of these products are majorly done by third party vendors presently. For example, Sysmex entered into an agreement with Dade Behring for the distribution of their products, which is now a part of Siemens Healthcare Diagnostics. But on the contrary this trend is expected to change in the forecasted period due to the increase in the investment to establish offices for distribution within multiple regions by the players leading to the rise in the momentum of direct supply agreements in the regions over the period of forecast.
Product Outlook (Revenue, USD Million, 2013 - 2024)
• Clinical Laboratory Analyzers
• Point of Care Analyzers
Technology Outlook (Revenue, USD Million, 2013 - 2024)
• Photo optical/Chromogenic/Immuno
Test Type Outlook (Revenue, USD Million, 2013 - 2024)
End-Use Outlook (Revenue, USD Million, 2013 - 2024)
• Research Institutes
• Diagnostic Centers
Regional Outlook (Revenue, USD Million, 2013 - 2024)
• North America
• Asia Pacific
• Latin America
• South Africa
Research Support Specialist, USA